Knight Therapeutics Inc
TSX:GUD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of Knight Therapeutics Inc (GUD) under the Base Case is 9.08 CAD per share. Compared with the current market price of 11.92 CAD, the stock appears Overvalued by 24% .
The intrinsic value is calculated using the DCF method. Net margin recovers from -1.2% last year to 9% by 2033. If net margin stayed at its five-year average of -1.8%, the estimate would be about CA$6.12. The value of the years after 2033 is tied to revenue, so margins count only until then.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Knight Therapeutics Does
Knight Therapeutics Inc. is a specialty pharmaceutical company that buys, licenses, and sells prescription medicines and hospital products. It does not usually discover drugs itself; instead, it focuses on bringing approved products from other companies into the markets where it has distribution and marketing rights. Its portfolio includes medicines for areas like oncology, infectious disease, and other specialty care settings.
- Headquarters
- Canada CA
- Employees
- 830
- IPO date
- Feb 28, 2014
Continue GUD Research
Decided on Knight Therapeutics? Get an email when GUD reaches the price you’d buy at. Free with an account.
Other Knight Therapeutics listings
What is the Intrinsic Value of one GUD stock?
The intrinsic value for Knight Therapeutics Inc (GUD) under the Base Case is 9.08 CAD.
Is GUD stock undervalued or overvalued?
Compared with the current market price of 11.92 CAD, the stock appears Overvalued by 24% .